Redox-sensitive factors as targets of thiol compounds to hinder SARS-CoV-2 replication and inflammatory response.
Level 5 - mechanism / opinion, no new human data
In vitro cell culture bench research without in vivo animal or human data.
PubMed 42524834 · doi:10.1128/aac.00518-26
What was done
Researchers investigated viral replication kinetics, cellular redox state (glutathione and cysteine levels), and inflammatory cytokine responses in SARS-CoV-2-infected Calu-3 and A549-ACE2/TMPRSS2 cells. They evaluated the effects of two thiol-derived compounds—I-152 (a monothiol conjugate of N-acetylcysteine and β-mercaptoethylamine) and its dithiol derivative I-152SdAc—on Nrf2-mediated gene expression (such as GCLM), the JNK/AP-1 pathway, and CHAC1, with key findings confirmed in normal human bronchial epithelial (NHBE) cells.
What was found
SARS-CoV-2 infection caused marked depletion of glutathione (GSH) and cysteine (Cys) at 48 hours post-infection, alongside activation of the JNK/AP-1 pathway and a strong pro-inflammatory cytokine response. Treatment with I-152 and I-152SdAc restored GSH balance by upregulating Nrf2-mediated genes, inhibited AP-1 signaling, and reduced both viral replication and inflammatory cytokine release in cell lines and NHBE cells. The abstract does not report specific numerical metrics, concentrations, or effect sizes.
Why it matters
These findings delineate host redox imbalance as a core pathogenic mechanism in SARS-CoV-2 infection and suggest that dual-acting thiol compounds targeting Nrf2 and AP-1 pathways warrant investigation as host-directed antiviral and anti-inflammatory candidates.
Limits
The study is entirely in vitro using immortalized and primary airway epithelial cell models; in vivo efficacy, pharmacokinetics, lung distribution, and clinical safety were not assessed. The abstract does not provide quantitative data, exact concentrations tested, or statistical effect estimates.
Cited by
- supports SARS-CoV-2 viral replication requires a reduction in cellular glutathione levels.